Table 3.
Evaluation of clinical manifestations and laboratory features amongst AML patients with low and high membrane protein expression of total B7-H3 isoforms
| Patient’s parameters | The whole AML patients |
||
|---|---|---|---|
| B7-H3low (n = 34) | B7-H3high (n = 28) | P | |
| Sex, male/female | 18/16 | 16/12 | 0.741 |
| Median age, years (range) | 54.5 (15–93) | 66 (32–90) | 0.077 |
| Median WBC, ×109 /L (range) | 18.6 (0.8–207.5) | 33.3 (0.8–158.7) | 0.581 |
| Median Hb, g/L (range) | 83 (45–141) | 88 (50–138) | 0.445 |
| Median Plt, ×109 /L (range) | 34 (5–192) | 35 (3–382) | 0.983 |
| BM blasts, % (range) | 50 (3.0*-94.0) | 64 (16.5*-93.5) | 0.471 |
| FAB classification | 0.345 | ||
| M0 | 2 (5.9%) | 0 (0.0%) | |
| M1 | 1 (2.9%) | 2 (7.1%) | |
| M2 | 16 (47.1%) | 9 (32.1%) | |
| M3 | 5 (14.7%) | 2 (7.1%) | |
| M4 | 6 (17.6%) | 8 (28.6%) | |
| M5 | 4 (11.8%) | 6 (21.4%) | |
| M6 | 0 (0.0%) | 1 (3.6%) | |
| Karyotype | 0.419 | ||
| Normal | 14 (41.2%) | 10 (35.7%) | |
| t(8;21) | 2 (5.9%) | 2 (7.1%) | |
| t(16;16) | 2 (5.9%) | 0 (0.0%) | |
| t(15;17) | 5 (14.7%) | 2 (7.1%) | |
| +8 | 1 (2.9%) | 1 (3.6%) | |
| −5/5q- | 1 (2.9%) | 1 (3.6%) | |
| −7/7q- | 0 (0.0%) | 1 (3.6%) | |
| t(9;22) | 1 (2.9%) | 0 (0.0%) | |
| Complex | 2 (5.9%) | 7 (25.0%) | |
| Others | 4 (11.8%) | 1 (3.6%) | |
| Not available | 2 (5.9%) | 3 (10.7%) | |
| Karyotype classification | 0.165 | ||
| Favorable | 9 (26.5%) | 4 (14.3%) | |
| Intermediate | 19 (55.9%) | 12 (42.9%) | |
| Poor | 4 (11.8%) | 9 (32.1%) | |
| Not available | 2 (5.9%) | 3 (10.7%) | |
| Gene Mutation | |||
| NPM1 (+/-) | 7/25 | 3/22 | 0.534 |
| CEBPA (+/-) | 8/24 | 3/22 | 0.370 |
| FLT3-ITD (+/-) | 4/28 | 7/18 | 0.257 |
| c-KIT (+/-) | 0/32 | 2/23 | 0.188 |
| N/K-RAS (+/-) | 6/26 | 3/22 | 0.743 |
| IDH1/2 (+/-) | 5/27 | 1/24 | 0.325 |
| DNMT3A (+/-) | 4/28 | 2/23 | 0.909 |
| U2AF1 (+/-) | 4/28 | 0/25 | 0.190 |
| SRSF2 (+/-) | 2/30 | 3/22 | 0.772 |
| SETBP1 (+/-) | 2/30 | 1/24 | 1.000 |
| TP53 (+/-) | 2/30 | 2/23 | 1.000 |
| CR (+/-) | 20/14 | 11/17 | 0.126 |
*:Diagnosis was done in regards to the World Health Organization criteria for patients with low percentage blasts (< 20%) in BM. The cytogenetic aberrations t (15;17) (q22; q12), were also detected in these patients. Abbreviations: AML = acute myeloid leukemia; WBC = white blood cells; Hb = hemoglobin; Plt = platelets; BM = bone marrow; CR = complete remission. P values were determined using χ2 test for the sex, karyotype, common gene mutations and CR rates after standard induction therapy for 2 cycles, and utilizing Mann-Whitney’s U test for the age, WBC, Hb, Plt and BM blasts.